#dexcom

[ follow ]
#oura

Oura valued at $5B following deal with medical device firm Dexcom | TechCrunch

Oura received a $75 million investment from Dexcom, integrating glucose monitoring with their smart rings to enhance user health insights.

Finnish smart ring maker OURA secures 71M investment; now valued at 4.7B+ - Silicon Canals

ŌURA secures $75M funding from DexCom to enhance metabolic health through data integration, providing insights on lifestyle choices related to glucose levels.

Here's How Oura Will Bring Blood Sugar Monitoring to Its Smart Rings

Oura partners with Dexcom to integrate glucose monitoring data into its smart ring ecosystem, enhancing user health insights.

Oura valued at $5B following deal with medical device firm Dexcom | TechCrunch

Oura received a $75 million investment from Dexcom, integrating glucose monitoring with their smart rings to enhance user health insights.

Finnish smart ring maker OURA secures 71M investment; now valued at 4.7B+ - Silicon Canals

ŌURA secures $75M funding from DexCom to enhance metabolic health through data integration, providing insights on lifestyle choices related to glucose levels.

Here's How Oura Will Bring Blood Sugar Monitoring to Its Smart Rings

Oura partners with Dexcom to integrate glucose monitoring data into its smart ring ecosystem, enhancing user health insights.
moreoura
#stock-market

3 Stocks Down 20% Or More That Are Must Buys Now

Stocks are generally up, making it hard to find good buying opportunities on dips.

Can These 3 Nasdaq 100 Laggards Rebound in September?

The Nasdaq 100 shows both extreme growth potential and vulnerability in turbulent market conditions.
Dexcom's recent performance raises concerns about its ability to rebound amidst competitive pressures.

3 Stocks Down 20% Or More That Are Must Buys Now

Stocks are generally up, making it hard to find good buying opportunities on dips.

Can These 3 Nasdaq 100 Laggards Rebound in September?

The Nasdaq 100 shows both extreme growth potential and vulnerability in turbulent market conditions.
Dexcom's recent performance raises concerns about its ability to rebound amidst competitive pressures.
morestock-market
[ Load more ]